Blog · NOV 5, 2025 · 4 min read

UCPMP 2024 One Year In: What Changed in Practice

A year into India's binding pharma marketing code, the paperwork changed fast. The behavior it was meant to change is catching up more slowly.

By Team Medismo•Compliance

UCPMP 2024 has been in force long enough now that we can talk about what actually changed on the ground, rather than what the code says on paper.

The biggest shift we have seen across the pharma teams we work with is documentation discipline. Gifting restrictions, honorarium caps, and disclosure requirements around doctor interactions are no longer treated as guidance to be interpreted generously. Compliance heads we talk to describe a real change in posture from legal and regulatory affairs teams, who now review field activity with the assumption that any interaction could be audited.

Where enforcement has bitten hardest

  • •Continuing medical education sponsorships now require far more detailed justification and record-keeping than a year ago
  • •Sample distribution logs are being reconciled against actual prescribing data in ways that were rare before
  • •Field teams report more scrutiny on informal doctor interactions that used to go unrecorded entirely
  • •Several companies have restructured their medical rep incentive models specifically to remove any link between gifting and prescription volume

The part that has not caught up

What has not caught up is verification. A compliance team can write a perfect policy on what an interaction should look like, but most companies still have no reliable way to confirm that a logged doctor visit actually happened, at the time and place claimed, with the content described. Self-reported field data has always had this gap, and UCPMP 2024 has simply raised the cost of that gap being exploited, whether deliberately or through simple sloppiness.

We hear this from almost every compliance head we talk to in some form: the code tells them what a compliant interaction looks like, but nothing in their current stack tells them whether the interaction they are reviewing actually happened that way.

That is the specific problem we have been building toward over the last few months. Structured scheduling solves half of it, by making the interaction a real calendar event rather than an unplanned drop-in. The other half is verification at the moment the visit occurs, which is a harder and more interesting engineering problem, and one we will be writing about in detail soon.

ucpmp-2024compliancepharma-marketing